Introduction
Hereditary spherocytosis refers to a group of heterogeneous inherited anemias that are characterized by anemia, jaundice, and splenomegaly. The clinical situation of the disease is often most severe during the first year of life, and most newborns have severe anemia, although it is improved after the first year of life. Jaundice is the first clinical situation in newborns, with severe anemia developing during the first few days after birth. Splenomegaly is a frequently observed feature (1) . The age of onset and severity of the disease vary considerably. Splenectomy is the first choice of treatment in some patients with symptomatic anemia as it eliminates the necessity of repeated transfusions. Recent evidence is emerging that splenectomy may have adverse vascular long term consequences, and whether patients should undergo splenectomy is controversial (2, 3) .
Hereditary spherocytosis is reported worldwide and is the most common hereditary anemia in individuals from northern Europe and northern America (4) (5) (6) (7) (8) (9) (10) . The prevalence of the disease is around 1 in 5,000 to 1 in 2,000 in the above two areas. The prevalence of hereditary spherocytosis in people of other ethnic backgrounds is unknown, but it is much less common. As a kind of rare disease, there is no exact prevalence of hereditary spherocytosis in China. Although China is also actively promoting regulation of rare diseases, the diseases have not been covered by the national health system. However, there are still no official data on "the prevalence of hereditary spherocytosis and the number of cases". So a crucial step is to collect data on hereditary spherocytosis in China. We searched the reported literature or cases in hospitals to obtain the data collection from China.
This study systematically reviewed hereditary spherocytosis reported in the Chinese biomedical literature published over the past 36 years from January 1978 to December 2013 and analyzed the current state and treatment of hereditary spherocytosis in China.
Summary
Epidemiological (11) . English terms for hereditary spherocytosis were included because most Chinese biomedical publications contain an English abstract. We collected literature related to clinical data, diagnostic information and laboratory data searched in the CBM database. Cases of hereditary spherocytosis with a confirmed diagnosis were included. For each study included, informed consent for publication was obtained from the patient. Patient medical information was carefully compared for series of reports by the same authors or institutions, and redundant cases were excluded.
Other data
The World Health Organization (WHO) and Harvard University designed DisMod-II software to calculate the burden of diseases. The software was used to estimate the prevalence of a simple disease model with four possible kinds of data, namely: incidence; mortality of the disease; all other mortality and remission. The model permits calculation of prevalence at a certain age of remission, the mortality and incidence in the age interval (12) .
The mortality of hereditary spherocytosis was selected from CDC WONDER (Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research) (http://wonder.cdc.gov/). The CDC WONDER is the nation's primary data repository for health statistics of the United States, which covers the CDC site data and statistical information service. Through the system, users can retrieve the morbidity and public health data including, scientific research data, survey data, health statistical data, laboratory information and so on (13) .
All other mortality was collected from the national disease surveillance system death surveillance data sets 2011 which was written by Chinese Center for Disease Control and Prevention that summarizes the national disease surveillance systems (DSPs) 2011 round of population and mortality data (14) .
The structure of the general population of China was obtained by the sixth national population census of the People's Republic of China, which was published in the National Bureau of Statistics of the People's Republic of China in 2010 (15). It is an agency within the State Council of the People's Republic of China charged with the collection and publication of statistics related to the economy, population and society of the People's Republic of China at national and local levels.
Statistical analysis
2.2.1. The literature data SPSS 21.0 was used to input and manage data, it was corrected in accordance with the original data when there was abnormal data or missing values. Descriptive statistical analysis was used for the frequency distribution analysis and description of the data characteristics. Charts were drawn with SPSS and Excel. A map with shades of color reflecting the number of hereditary spherocytosis cases in each city was created with ArcMap 10.0.
Prevalence of hereditary spherocytosis
We selected year 2011 for calculation purposes as this was the latest year for which all other mortality data of China were available. The patients of hereditary spherocytosis were selected from the literature data in 2011, then we used the number of patients from 2011 and the structure of the general population of China to calculate incidence. All data were classified by gender and age group because of the requirements of DisMod-II software.
The Multiple Cause of Death database contains mortality and population counts for all USA counties from 1999 to 2013. We extracted deaths from hereditary spherocytosis of 15 years data, then calculated the average mortality which were broken down by gender and age group.
Hereditary spherocytosis is the only congenital hemolytic anemia for which a splenectomy proves consistently beneficial. Recent evidence is emerging that there may be adverse long term vascular consequences of splenectomy, whether patients should undergo splenectomy is controversial and splenectomy does not eradicate birth defects. So remission was assumed to be zero. Finally, the model was constructed using hereditary spherocytosis mortality data in USA, and remission. All other mortality was also introduced into the model, along with the national disease surveillance system the age of 55. We also estimated that China has 8,644 males and 9,667 females hereditary spherocytosis sufferers (Figure 4) . The prevalence calculated from national and literature data by the DisMod-II software death surveillance data sets 2011 of China. Then the ensuing estimates of prevalence were shown by age group and gender.
Results
373 reports were searched in CBM database, 297 reports were qualified for inclusion according to our criteria. A total of 2,043 cases of hereditary spherocytosis were reported in the literature. As shown in Figure 1 , the number of patients with hereditary spherocytosis reported each year in the CBM database, after 1994 is significantly higher than a few years ago. 71% of the cases were diagnosed at a university hospital, 22% were diagnosed at a municipal hospital, 4% were diagnosed at a provincial hospital, and the remainder (3%) was diagnosed at hospitals on country level or even from smaller communities (Figure 2) . The geographic distribution of reported patients is shown in Figure 3 . From the map view, more cases were reported in the South and East of China, which have a higher population density and better medical services than other areas. Shandong, Beijing, Liaoning, Hebei and Shanghai ranked among the top 5 provinces or province level municipalities where disorders were reported. In Xizang, Qinghai and Guizhou only a few cases were reported.
In 2011, the number of cases was 114 reported from CBM database, the male: female ratio was 1.04:1. According to the sixth national population census of the people's republic of China, Chinese population totaled 1,332,810,869, with a breakdown by sex of 682,329,104 males and 650,481,765 females. In 2011, overall literature reported prevalence of hereditary spherocytosis in China was estimated to be: 1.27 cases per 100,000 people in males and 1.49 cases per 100,000 people in females (Table 1) . From the table we found that the model estimated incidence of hereditary spherocytosis was high before the age of 15 and after 71% of the cases were diagnosed at a university hospital, 22% at a municipal hospital, 4% at a provincial hospital, and the remainder (3%) was diagnosed at hospitals on country level or even from smaller communities.
is shown in Figure 5 . The model estimates an increase with age but with a slower pace, after 65 years cases increase suddenly and at ages > 85 years the estimates reach a maximum.
Discussion
Hereditary spherocytosis is a rare disease, there is no cure for hereditary spherocytosis caused by genetic defect, and thus the focus of current management is to limit the severity of the disease. Treatment options include: splenectomy and partial splenectomy, even cholecystectomy. Splenectomy is the most effective way of treatment and will be of benefit in all people with severe as well as some people with moderate hereditary spherocytosis, but is not usually necessary in mild cases. Recent evidence demonstrates that splenectomy for hereditary spherocytosis is safe in the short term, studies showed no deaths and infrequent complications in 1,657 children (16) . The disadvantages of splenectomy are large trauma and significant immunity decline. Partial splenectomy applied to the young, yields low immunity, and splenectomy might cause serious infection of patients who may relapse again. Investigators finished a follow-up of 10 years and found that 7.5% cases needed a total splenectomy again (17) .
From the results of publications in CBM database, the number of hereditary spherocytosis cases increased significantly after 1994, and in the last 10 years there were 979 cases that accounted for nearly 1/2 of the reported numbers. This situation is because general healthcare has improved rapidly and people pay more attention to medical problems caused by rare diseases in China. Cases were more frequently reported around the Bohai area which contains Beijing, Shandong, Liaoning and Hebei. We noted that more university hospitals and blood institutes are in these provinces. Also cases were more reported in large cities instead of areas with a larger population but a relatively lower level of development such as Guizhou and Sichuan Provinces and even Xizang found no reported cases. Country level hospitals and below represent more than 70% of the medical resources in China, but only 3% of the cases of hereditary spherocytosis were diagnosed by these hospitals. There are also some disparities between university hospitals and provincial and municipal hospitals. So, countries should pay more attention to reform health care and improve the level of medical technology of country level hospitals and below. At the same time, a stronger network of diagnosis and treatment including all levels of hospitals should be created to improve healthcare for hereditary spherocytosis and other rare diseases in the future.
Although hereditary spherocytosis is encountered worldwide, its prevalence in other groups (excluding northern European and northern American groups) has not been clearly established. Currently, there is no case registration system for most rare diseases in China, so there is very little information on the epidemiology of hereditary spherocytosis. To our knowledge, a systematic survey of the literature was being performed in order to provide an estimated prevalence of rare diseases or the reported number of published cases in Europe. The prevalence of hereditary spherocytosis was 1/5,000 in Europe which was published on orphanet (the portal for rare diseases and orphan drugs) in May 2014 (18) .
DisMod-II was designed as a system to assist in the burden of disease models in the 1990s, and in a few exceptional cases, to estimate disease prevalence (19) (20) (21) . DisMod-II has seven kinds of possible input variables: incidence, remission, case fatality rate, mortality, prevalence, duration and relative risk of death. In general, three input variables are needed to calculate the other four variables and the age of onset. When there are less than three available variables, we can use expert judgment to obtain additional information. The greatest source of error may be from using information that has a lack of data or a small sample size that represents large groups. But the model is fairly robust, it will reasonably allow an estimate of the prevalence, which is comparable with figures reported by published studies. Traditional prevalence studies require more time to collect and calculate data, and only allow input of the number of cases and time or incidence and duration. Nevertheless, DisMod-II permits modelling of variability situations, such as entering different models of remission, incidence and case fatality rate. DisMod-II should be the most effective way to estimate the prevalence of rare diseases.
The model is based on the assumption that incidence and mortality are in a steady state, but it is dependent on the incidence and mortality from the past as well as the present (22) . The incidence of hereditary spherocytosis was collected and calculated from CBM database reported in 2011, although it would not represent all cases. The mortality of hereditary spherocytosis was selected from CDC WONDER and was an average mortality between 1999 and 2013 in USA. In conclusion, our analysis suggests that previous estimates of prevalence, based on smaller datasets, have underestimated the prevalence of hereditary spherocytosis in China. In the future, we can collect more information from medical record registration systems in hospitals to estimate an accurate prevalence.
Conclusion
In conclusion, this systematic review summarized the number of cases and geographic areas of hereditary spherocytosis in China Biology Medicine disc and also estimated the literature reported prevalence of hereditary spherocytosis by DisMod-II software in China. Analyzing the number of cases indicated an imbalance in the distribution of areas and hospitals diagnosis, which suggests a stronger network of diagnosis and treatment including all levels of hospitals that should be created to improve healthcare for hereditary spherocytosis and even other rare diseases in the future. Then we can have more accurate information to estimate prevalence. In addition, through DisMod-II software we can obtain more useful information for orphan drug designation purposes and make public health decisions regarding such diseases.
